New prostate cancer diagnoses increased 12.08% and prostate-specific antigen screenings increased 52.18% between 2021 and 2024, according to data published Feb. 12 by Epic Research.
Epic’s research division utilized data from Cosmos, a dataset created in collaboration with a community of Epic health systems representing more than 300 million patient records from the U.S., Canada, Saudi Arabia and Lebanon.
Men ages 35-44 and 55-64 experienced the largest increase in new cancer diagnoses between 2021 and 2024 at 22.81% and 22.85%, respectively.
Men ages 35-44 also experienced the largest increase in PSA screenings, with screening rates jumping 60.18% between 2021 and 2024.
Prostate cancer accounts for 30% of all male cancers and is the second-leading cause of cancer death for men behind lung cancer. According to a recent study, prostate cancer incidence in the U.S. increased 3.0% per year between 2014 through 2021, following almost a decade of decline.
Here are the changes in new prostate cancer diagnoses and PSA screenings between 2021 and 2024, according to Epic Research:
| New cancer diagnoses per 100,000 patients | |||
| Age | Q1 2021 | Q4 2024 | Percentage change |
| 35-44 | 5.7 | 7 | 22.81% |
| 45-54 | 59.2 | 68.3 | 15.37% |
| 55-64 | 203.5 | 250 | 22.85% |
| 65-74 | 356.7 | 411.4 | 15.34% |
| 75-84 | 361.2 | 403.6 | 11.74% |
| 85+ | 326.3 | 330.8 | 1.38% |
| 35-85+ | 1312.6 | 1471.1 | 12.08% |
| PSA screenings per 100,000 patients | |||
| Age | Q1 2021 | Q4 2024 | Percentage change |
| 35-44 | 1,175.9 | 1,883.5 | 60.18% |
| 45-54 | 4,656.7 | 7,137.7 | 53.28% |
| 55-64 | 6,497.3 | 9,696 | 49.23% |
| 65-74 | 5,736.1 | 8,725.4 | 52.11% |
| 75-84 | 3,427.3 | 5,275 | 53.91% |
| 85+ | 1,515 | 2,296.1 | 51.56% |
| 35-85+ | 23,008.3 | 35,013.7 | 52.18% |
Leave a Reply